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Background: CYP2C19*2 polymorphism is related to metabolizer phenotypes resulting in reduced effectiveness in
converting the antiplatelet drug clopidogrel to active drug. An association of the genotype itself with adverse
outcomes is discussed. We investigated the prognostic value of carriage of the CYP2C19*2 allele in a high risk
group of patients with prevalent coronary heart disease (CHD) at baseline during long-term follow-up under
conditions of routine clinical care.
Methods: In n=1050 patients with stable CHD at baseline genotyping of CYP2C19 allele *2 (rs4244285; 681G>A)
was performed. The Cox-proportional hazards model was employed to investigate the association of CYPC19*2
allele status with cardiovascular disease (CVD) events during eight year follow-up. The analysis was also performed
in patients who did not take clopidogrel or ticlopidin.
Results: Only the very few patients homozygous for a loss-of-function variant of CYP2C19, allele *2 (2.6%), had a
statistically significantly higher incidence rate for secondary CVD events during long-term follow-up than wild-type
carriers (50.8 versus 21.5 per 1000 patients years; rate for heterozygous carries 17.2 per 1000 patient years). The
hazard ratio after adjustment for covariates compared to the wild-type carriers was 2.59 (95% confidence interval
(CI) 1.27-5.28) and 0.80 (95% CI 0.52-1.23) for homozygous and heterozygous allele carriers, respectively.
Conclusions: In this medium-size group of patients with stable CHD homozygous carriers of the loss-of-function
allele CYP2C19*2 were at increased risk for subsequent CVD events during 8 year follow-up independent of other
risk factors. As only few patients carried the homozygous loss-of-function variant and we found overall no evidence
for improved clinical utility, a benefit of genotyping in this patient population seems unlikely.* Correspondence: dietrich.rothenbacher@uni-ulm.de
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In the meantime a one-year dual antiplatelet therapy is
standard treatment for patients with acute coronary
syndrome (ACS) and percutaneous coronary intervention
(PCI) for secondary prevention of thrombo-occlusive car-
diovascular complications [1]. Various genetic factors have
been identified that seem to hamper this preventive con-
cept, especially polymorphisms related to metabolizer
phenotype [2]. Cytochrome P450 2 C19 is a mixed-
function oxidase of the P450 cytochrome family that is
mostly involved in metabolizing xenobiotics in the body,
and in synthesis of cholesterol and other lipids. There are
several polymorphisms for this gene which influence the
presence and activity of the enzyme.
The most common alleles that result in the poor
metabolizer phenotype are the *2 and *3 alleles. The car-
riage of *2 allele has been described in 95% of poor
metabolizers [3]. Poor metabolizers have an impaired ef-
fectiveness in converting the antiplatelet drug clopidogrel
to the active drug to exert its antiplatelet effect. In a
cohort of healthy subjects carriage of at least one
CYP2C19*2 reduced-function allele resulted in a relative
reduction of 32.4% in plasma exposure to active clo-
pidogrel [4]. In a separate cohort of patients with ACS *2
carriers also had a higher rate of major cardiovascular
events compared to non-carriers [4]. In contrast, Pare and
colleagues presented data from two large randomized con-
trolled trials showing no association between increased
cardiovascular risk and CYP2C19 loss of function variants
[5]. The latter may have been caused by the comparison
of loss-of-function allele carriers taking clopidogrel with
those taking placebo, which showed that carriers taking
clopidogrel still had improved outcomes compared to
placebo. A collaborative meta-analysis conducted by
Mega et al. [6] including patients with acute coronary
heart disease (CHD) and treated with clopidogrel showed
that carriage of even one reduced-function CYP2C19
allele was associated with a significantly increased risk of
adverse cardiovascular events.
Current evidence suggests that the CYP2C19 poly-
morphisms may be clinically relevant mainly through
the effects on metabolism of clopidogrel prodrug, but
further data are needed to determine if other mecha-
nisms are possible too and whether routine testing at
the point of care may be beneficial for the patients [7].
The Food and Drug Administration (FDA) released a
Boxed Warning in the year 2010 that patients with a
poor metabolizer phenotype may not effectively meta-
bolize clopidogrel prodrug and therefore may not ex-
perience its full benefits [8]. Although the impact of the
CYP2C19 polymorphisms on the functional conse-
quences on enzyme activity are well understood [2,3]
and an increased risk for major adverse cardiovascular
risk in subjects taking clopidogrel has been suggested[4], the question whether variants of CYP2C19 are asso-
ciated with an adverse outcome itself, independent of
clopidogrel intake is still discussed. This is relevant
given that antiplatelet therapy is recommended only for
one year for patients with ACS or PCI [1]. Therefore,
more information is needed to further understand the
relationship between genotype, clopidogrel intake and
subsequent risk for secondary cardiovascular disease
events, especially in high CHD risk-patients from rou-
tine clinical care.
We investigated the prognostic value of carriage of the
CYP2C19*2 allele in a high risk group of patients with
prevalent CHD at baseline during long-term follow-up
of eight years under conditions of routine clinical care
and considering other concurrent risk factors. We were
also investigating whether carriage of the CYP2C19*2
allele itself is associated with an adverse outcome in
patients not taking dual-platelet therapy.
Methods
Study population
All patients with CHD (International Classification of
Diseases, 9th Rev. codes. 410–414) aged 30–70 years and
participating in an in-hospital rehabilitation program bet-
ween January 1999 and May 2000 in two cooperating hos-
pitals (Schwabenland-Klinik, Isny and Klinik im Südpark,
Bad Nauheim, Germany) were enrolled in the study
(response at baseline 58%). In Germany, all patients after
an acute coronary syndrome (ACS) or elective coronary
artery bypass grafting (CABG) are offered a compre-
hensive in-hospital rehabilitation program following their
discharge from the acute care hospital. The aim of this
3-weeks program is the reduction of cardiovascular risk
factors, improvement of health related quality of life, and
the preservation of the ability to work (the latter only if a
subject was still at work at the onset of disease, otherwise
the prevention of need for nursing care). This in-hospital
rehabilitation program usually starts approximately three
weeks after the acute event or CABG. In the current
study, only patients who were admitted within three
months after the acute event or CABG were included.
Further details can be found elsewhere [9].
All subjects gave written informed consent. The study
was approved by the Ethics Boards of the Universities of
Ulm and Heidelberg and of the Physicians’ chamber of the
States of Baden-Wuerttemberg and Hessen (Germany).
Data collection
At the beginning of the in-hospital rehabilitation pro-
gram all subjects filled out a standardized questionnaire
containing socio-demographic information and medical
history. In addition, information was taken from the
patients’ hospital charts. In all patients active follow-up
was conducted 1, 3, 4.5, 6 and 8 years after discharge
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from the patients using a mailed standardized question-
naire. Information regarding secondary cardiovascular
disease (CVD) events and treatment since discharge from
the in-hospital rehabilitation clinic was obtained from the
primary care physicians by means of a standardized ques-
tionnaire. If a patient had died during follow-up, the death
certificate was obtained from the local Public Health
Department and the main cause of death was coded
according to the International Classification of Diseases
(ICD-9 pos. 390–459: ICD-10 pos. I0-I99 and R57.0).
Secondary CVD events were defined as CVD as the main
cause of death (as stated in the death certificate), non-fatal
myocardial infarction (MI), or non-fatal ischemic stroke.
All non-fatal secondary events were reported by the
primary care physicians.
Laboratory methods
Genotyping of one single-nucleotide polymorphism (SNP)
defining the CYP2C19*2 allele (rs4244285;681G>A) was
performed with a TaqMan assay of ABI (C__25986767_70;
Applied Biosystems, Foster City, CA) from stored peri-
pheral blood DNA. The deviation from Hardy-Weinberg
equilibrium was non-significant.
Blood at baseline was drawn at discharge from the re-
habilitation centre on average 43 days after the acute
event (1st quartile 36 days, 3rd quartile 51 days) in a
fasting state under standardized conditions and stored
at −80°C until analysis. C-reactive protein (CRP) con-
centrations were measured by immunonephelometry
on a Behring Nephelometer II (N Latex CRP mono
Dade-Behring, Marburg). Cystatin C was determined
on the same device (Dade-Behring, Marburg). NT-
proBNP was measured by electrochemiluminescence
on an Elecsys 170 (Roche Diagnostics, Mannheim,
Germany). Inter-assay coefficients of variation (CVs)
were 4.1% for CRP, 3.8% for cystatin C, between 3% and
7% for NT-proBNP. All markers were measured in a
blinded fashion. Creatinine, blood lipids and leukocyte
count were done by routine methods in both participating
hospitals.
Statistical methods
The study population was described with respect to va-
rious sociodemographic and medical characteristics. If
variables were normally distributed, means and standard
deviation were given, otherwise median and interquartile
range. We also calculated a modified version of the
GRACE score as published by Eagle and colleagues to
describe the risk for subsequent mortality [10]; the only
variable among the nine variables contained in the score
we could not include was ST-segment depression at the
index events, since we did not have information on all
subjects for it. The associations of sociodemographiccharacteristics, various cardiovascular risk factors, severity
of cardiovascular disease, and medication with CYP2C19*2
allele status (GG, AG, AA; AA or AG versus GG) were
quantified by means of the nonparametric Kruskal-Wallis
test (an exact test was used if cell number was n< 5). In
addition mean values, adjusted for age and gender, were
calculated for categories of CYPC19*2 allele status and
body mass index, blood lipids, CRP, IL-6, creatinine
clearance, cystatin C, NT-proBNP and quantified by a
respective p-value.
The relation of CYP2C19*2 allele status with CVD
events during follow-up was assessed by the Kaplan-
Meier and life table method and quantified by means of
the log-rank test. Then the Cox proportional hazards
model was employed to assess the independent asso-
ciation of CYP2C19*2 allele status with the risk of
secondary CVD events (hazard ratios, HR, and their
95% confidence intervals, CI). A basic model was
adjusted for age (years) and gender. In a second step,
beside the main factor CYP2C19*2 allele status, the va-
riables age and gender, the following potential con-
founders were considered in multivariable analyses:
hospital site, body mass index (BMI, kg/m2), school dur-
ation (< 10 years, ≥10 years), smoking status (never,
current, ex-smoker), history of diabetes mellitus (yes,
no), initial management of CHD (conservative, percu-
taneous coronary intervention, PCI, CABG), left ven-
tricular function (degree of impairment: no or little,
modest severe, unknown), intake of lipid-lowering drugs
(yes, no), HDL-cholesterol (mg/dl), LDL-cholesterol
(mg/dl), and NT-proBNP, and finally intake of
clopidogrel. Finally we excluded all patients with a
clopidogrel and ticlopidine intake at baseline and one-
year follow-up to investigate the association of the
CYP2C19*2 allele itself with the outcome. All statistical
procedures were carried out with the SAS statistical
software package (release 8.2, Cary, NC (USA), SAS
Institute Inc. 1999).
Results
Overall, 1,206 patients with a diagnosis of CHD within
the past 3 months were included at baseline during the
in-hospital rehabilitation program. Eight-year follow-up
information was complete for 1,050 patients (87.1%, all
of Caucasian origin). The main characteristics of the
study population are shown in Table 1. The mean age of
the study population at baseline was 58.8 years, most of
the patients were male (85.0%). A history of myocardial
infarction or diabetes was reported by 58.2% and 17.7%,
respectively. A 3-vessel disease was present in 42.8% of
the CHD patients at baseline. For the CYP2C19*2
polymorphism 26.6% were heterozygous, and 2.6% were
homozygous poor metabolizers with a loss-of-function
gene.
Table 1 Sociodemographic, clinical, and laboratory
characteristics in 1,050 patients with clinically manifest
coronary heart disease
Characteristics at baseline
Age (years) (μ, SD) 58.8 ± 8.0
Men, n (%) 892 (85.0%)
CYP2C19C*2 allele frequency
- AA 27 (2.6%)
- AG 279 (26.6%)
- GG 744 (70.9%)
History of myocardial infarction, n (%) 611 (58.2%)
History of heart failure, n (%) 128 (12.6%)
Clinical score (angiographic evaluation)
- 1 vessel disease 255 (24.3%)
- 2 vessel disease 279 (26.6%)
- 3 vessel disease 449 (42.8%)
- unknown 52 (5.0%)
School education <10 yrs., n (%) 625 (59.5%)
Body mass index (kg/m2), (μ, SD) 27.1 ± 3.5
History of diabetes, n (%) 184 (17.7%)
Total cholesterol (mg/dl) (μ, SD) 168.9 (32.6)
LDL-cholesterol (mg/dl) (μ, SD) 100.4 (28.9)
HDL-cholesterol (mg/dl) (μ, SD) 39.4 (10.5)
C-reactive protein (mg/L) * 3.47 (1.23; 8.37)
Creatinine Clearance (mL/min) * 93.75 (78.20; 115.00)
Cystatin C (mg/L)* 1.03 (0.93; 1.19)
NT-proBNP (pg/mL)* 572.00 (279.90; 1101.00)
GRACE Score (points) (μ, SD) 95.9 (20.8)
* median, 25th and 75th quantile cut-point.
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function gene carrier status according to various so-
ciodemographic, and clinical findings. Homozygous
CYPC19C*2 carriers were more prevalent in males,
most prevalent in the youngest category (8.7% in those
30–39 years), and more often belonged to the category
with less than 10 years of school education. In addition
current smokers had the highest prevalence of homo-
zygous CYPC19*2 gene. However, the small numbers
of homozygous carriers needs to be considered.
At entry into the inpatient rehabilitation n=257
(24.5%) patients received clopidogrel (prescribed in the
acute care-hospital); at discharge from in-patients
rehabilitation only n=80 (7.6%) received it. In addition,
prescription went further down at 1 year follow-up
(n=50, 4.7%) (data not shown).
Table 3 shows the age and gender adjusted mean
values between CYP2C19C*2 loss of function gene
carriers and laboratory measures. The only statistically
significant differences were seen with total cholesteroland LDL cholesterol in the sense that patients with one
CYP2C19*2 allele all had the highest values.
During a mean follow-up of 8.1 years, 150 patients
(14.3%) experienced a secondary CVD event (n=59 (39%)
CV death, n=50 (33%) nonfatal MI, and n= 41 (27%) non-
fatal stroke). Figure 1 shows Kaplan-Meier survival curves
of time to secondary CHD event in patients with and
without CYPC19*2 loss-of-function gene. Overall, patients
homozygous for the CYP2C19*2 loss-of-function gene
had the highest incidence rate (50.8 per 1000 patient
years) (log rank test: p=0.01). After exclusion of all
patients with a clopidogrel and ticlopidine intake at base-
line and one-year follow-up (n=87, 80 received clopidogrel
and 7 received ticlopidine) the results were quite similar
(p=0.04) (Figure 2).
Table 4 shows the results of multivariable analysis.
Homozygous carriers of the CYP2C19C*2 allele showed
a HR of 2.59 (95% CI 1.27-5.28) after adjustment for
covariates, whereas patients with one CYP2C19*2 allele
showed no increased risk (the additional adjustment for
CRP and Cystatin C increased the risk for homozygous
carriers of the CYPC19C*2 to 2.76 (95% CI 1.35-5.66),
but no meaningful change was seen for the heterozygous
ones). If treatment with clopidogrel or ticlopidine was
considered in homozygous carriers of the CYP2C19C*2
allele only 2 patients were affected of whom one showed
a cardiovascular event during follow-up.
Adjustment for co-administration of PPI and calcium
antagonists, which also act as substrate and inhibitor for
CYP2C19, only marginally changed the prognostic value
of the CYP2C19 *2 allele and showed no association
with the outcome. Also if PPI and calcium antagonists
were considered as simultaneous medication, no in-
crease of risk was seen, but it has to be considered that
only 4 patients had this combination (data not shown).
Patients who did undergo stenting during initial treat-
ment showed similar risk patterns (HR for homozygous
carriers of the CYPC19C*2 was 2.78 (95% CI 1.01-7.69)
as the overall study population. After exclusion of
patients on clopidogrel or ticlopidin homozygous car-
riers of the CYP2C19C*2 allele showed still a HR of 2.27
(95% CI 1.06-4.86) after adjustment for covariates.
Table 5 shows that the addition of CYP2C19 informa-
tion to the risk prediction model did not add incremental
information to parameters of model fit, discrimination
and calibration, not demonstrating any clinical utility in
this patient population.
Discussion
In this medium-size cohort study of patients with stable
coronary heart disease at baseline only few patients homo-
zygous for a loss-of-function variant of the CYP2C19*2,
allele, compared to the wild-type carriers, showed a statis-
tically significant higher risk for secondary CVD events
Table 2 CYP2C19C*2 allele status according to various sociodemographic characteristics, cardiovascular risk factors,
and ECG findings at baseline
N CYP2C19C*2 allele
status (row%) (AG or AA)
p-value CYP2C19C*2 allele
status (row%) (AA only)
p-value*
All 1050
Gender - Female 158 26.6 1.9
- Male 892 29.6 0.44 2.7 0.75
Age (years) - 30-39 23 47.8 8.7
- 40-49 133 21.1 1.5
- 50-59 304 30.3 2.6
- 60-70 590 29.7 0.04 2.5 0.10
School education - < 10 yrs. 625 31.2 3.8
- ≥ 10 yrs. 425 26.1 0.08 1.8 0.008
Body mass index (kg/m2) - < 25 299 26.4 3.0
- 25-30 560 30.7 3.0
- >30 190 28.4 0.41 0.5 0.18
Smoking status - Never 333 28.8 1.2
- Ex 664 29.2 3.2
- Current 53 30.2 0.98 3.8 0.34
History of diabetes - Yes 184 28.8 2.7
- No 866 29.2 0.91 2.5 0.94
History of MI - Yes 611 30.9 2.6
- No 439 26.7 0.13 2.5 0.31
History of hypertension - Yes 583 29.5 2.7
- No 467 28.7 0.77 2.4 0.92
History of heart failure - Yes 128 25.0 2.3
- No 891 29.6 0.28 2.6 0.58
Angiographic score (number of
affected vessels)
- Zero/one 270 28.2 1.1
- Two 279 30.5 3.6
- Three 449 29.4 0.84 2.7 0.46
Initial management of CHD - Conservative 193 25.4 1.6
- PCI 361 28.8 2.8
- CABG 496 30.9 0.36 2.8 0.68
Left ventricular function* (degree
of impairment)
- No/only little 746 28.7 2.6
- Modest/severe 217 29.5 3.2
- Unknown 87 32.2 0.79 1.2 0.79
Lipid-lowering agent - Yes 810 28.9 2.6
- No 238 29.8 0.78 2.5 0.96
Beta-blocker - Yes 916 28.9 2.5
- No 132 30.3 0.75 3.0 0.87
Calcium antagonist - Yes 86 27.9 3.5
- No 962 29.2 0.80 2.5 0.67
ACE inhibitor - Yes 557 28.4 2.5
- No 491 29.9 0.58 2.7 0.86
Diuretic - Yes 255 31.0 2.4
- No 793 28.5 0.45 2.7 0.68
ASA - Yes 915 29.0 2.7
Rothenbacher et al. BMC Cardiovascular Disorders 2013, 13:61 Page 5 of 11
http://www.biomedcentral.com/1471-2261/13/61
Table 2 CYP2C19C*2 allele status according to various sociodemographic characteristics, cardiovascular risk factors,
and ECG findings at baseline (Continued)
- No 133 30.1 0.79 1.5 0.69
Clopidogrel or Ticlopidine - Yes 87 33.3 2.3
- No 963 28.8 0.37 2.6 0.59
Proton Pump Iinhibitor (PPI) - Yes 66 33.3 0.0
- No 984 28.9 0.44 2.7 0. 25
Clopidogrel or Ticlopidine or PPI - Yes 141 34.0 1.4
- No 909 28.4 0.17 2.8 0.18
*=Fishers Exact Test.
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covariates. The increased risk was independent of the co-
administration of PPIs, which may lead to further
functional variability in the P450 isoenzyme activity. An
increased risk was also suggested by the CYP2C19*2 geno-
type alone, respectively in patients without clopidogrel
(or ticlopidine) intake. Results of this study suggest that,
although the CYP2C19*2 genotype alone may eventually
carry independent prognostic information and may be
useful in identifying patients at increased risk for subse-
quent complications, the fact that very few patients
were affected with the homozygous loss-of-function has
to be considered. The latter makes it difficult to demon-
strate a clinical benefit of genotyping in this patient
population.
Our data add to the evidence from clinical trial popu-
lations indicating an increased risk in carriers of the
CYP2C19*2 loss-of-function allele compared to non-
carriers taking clopidogrel [3,6,11]. Although the prevalence
of the homozygous carriers was low in our populations and
the clinical relevance for the overall population of patients
with stable CHD may be limited, the associated risk with a
secondary CVD event for the few affected patients may be
high. However, today, all patients after drug eluting stent
implantation may be on P2Y12 inhibitors, predominantly
on clopidogrel. We did not find an increased risk for
the heterozygotes with one normal CYP2C19*2 allele.
This is in line with the results of a meta-analysis of
Holmes and colleagues [12] who compared individuals
with any copy of CYP2C19 genetic variants (alleles *2
through *8); presumably, the vast majority of subjects
carried a heterozygous genotype. Although they found a
higher risk for CVD events of 1.18 (95% CI 1.09-1.28)
using fixed-effects models and of 1.34 (95% CI 1.15-1.56)
for a random effects model, there was a trend towards the
null in larger studies consistent with small study bias and
they concluded that there was no association of genotype
with CVD events. Unfortunately, they did not further
characterize the risk of the homozygous carriers. A very
recent study conducted in n=506 patients with CAD fromChina also found an additional increased risk for adverse
cardiovascular outcomes independent from taking
clopidogrel, which was still present but was considerably
reduced in the second year of follow-up [13]. Various al-
leles have been identified for CYP2C19 of which several
combinations result in different metabolizer phenotypes
[14]. The most common CYP2C19*2, which was the sub-
ject of our study, is present in 95% of the patients with a
poor metabolizer phenotype [3]. We did not observe an
adverse association of the loss-of-function gene carrier
status with other concurrent CVD risk factors such as dia-
betes, lipid values, inflammatory parameters, or markers
of renal function, making the probability of confounding
by these risk factors unlikely. In addition all of them had
been controlled for in the final multivariable analysis.
Unfortunately we have no measure of platelet activity
included to further demonstrate the pharmacogenetic
and pharmacokinetic effects of CYP2C19*2. In patients
of Caucasian origin undergoing PCI (n=738) carriers of
the *2 allele showed a significantly higher adenosine di-
phosphate (ADP)-induced platelet aggregation and the
prevalence of this allele was 1.9% [15], which is a little
lower than in our study. The study of Shuldiner and col-
leagues in 429 Amish generally healthy white partici-
pants found that the CYP2C19*2 genotype was
associated with a diminished platelet response of
clopidogrel on inhibition of ADP induced platelet aggre-
gation [16]. In a separate population of 227 patients
undergoing PCI between 2004 and 2007 the study
showed that carriers of the CYP2C19*2 allele had twice
the risk of having a cardiovascular event during the
one-year follow-up.
Our study results are in line with the recent Black Box
Warning issued by the Food and Drug Administration
(FDA) that patients carrying the CYP2C19*2 allele should
receive other antiplatelet medication than clopidogrel or
alternative dosing strategies [8]. It has been suggested that
other anti-platelet medication such as prasugrel or tica-
grelor in combination with the CYP2C19*2 allele may not
result in an impaired prognosis [11]. Future studies,
Table 3 Age and Gender Adjusted Mean Values of Body Mass Index and Various Biomarkers according to CYP2C19C*2
Allele Status
CYP2C19C*2
allele status GG AG orAA
CYP2C19C*2 allele status GG AG AA
p-value p-value
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of loss-of-function allele carriers can be decreased in
general by using other pharmacologic strategies in rou-
tine clinical care. As the CYP2C19*2 genotype may only
account for about up to 12% of the clopidogrel response
[16], the higher percentages may only be found in
homogeneous populations, other relevant factors such
as diabetes or age may play a role, too. Although the
bedside-genotyping may be of additional value to gather
prognostic information, especially for the few homozy-
gous CYP2C19*2 loss-of-function carriers, as theassociation with an adverse cardiac outcome seems evi-
dent for these patients, the consequences for a modified
treatment schedule are not clear yet.
We did not find an interaction of the CYP2C19 poly-
morphism with concomitant intake of PPIs, known to be
strong inhibitors of the CYP2C19 activity and therefore
may increase the risk of thrombosis [17]. Although a phar-
macokinetic and pharmacogenetic interaction has been
described, the clinical consequences of this combination
and the relationship to adverse clinical outcomes such as
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Figure 1 Kaplan-Meier Estimates of Secondary Fatal and Non-Fatal CVD Events During Follow-Up (time=days) According to
CYP2C19C*2 Allele Status.
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Figure 2 Kaplan-Meier Estimates of Secondary Fatal and Non-Fatal CVD Events During Follow-Up (time=days) According to
CYP2C19C*2 Allele Status in Patients with no Intake of Clopidogrel or Ticopidine at Baseline and One Year Follow-up).
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vations, although the limited sample size and the relatively
rare use of clopidogrel a decade ago in this routineclinical care setting of our study population may only
allow excluding a strong effect. We did also not find an
association with the outcome of PPIs and simultaneous
Table 5 Measures of model accuracy with and without
CYP2C19C*2 status information (n=1050)























* adjusted for age, gender, BMI, school education, , rehabilitation clinic,
smoking status, history of diabetes mellitus, PCI, CABG, left ventricular
function, HDL-cholesterol, LDL-cholesterol, treatment with lipid-lowering
drugs, NT-proBNP [pg/mL].
Table 4 Association of CYP2C19C*2 allele status with
fatal and non-fatal cardiovascular events during
follow-up
Results of multivariable analysis
HR (95% CI) Adjusted
for age and gender




GG 1 referent 1 referent
AG 0.79 (0.54-1.17) 0.80 (0.52-1.23)
AA 2.37 (1.20-4.68) 2.59 (1.27-5.28)
p for trend 0.66 p for trend 0.45
After exclusion of patients on clopidogrel or ticlopidin
(n total = 963):
CYP2C19C*2
Allele status
GG 1 referent 1 referent
AG 0.82 (0.55-1.23) 0.87 (0.56-1.35)
AA 2.18 (1.06-4.49) 2.27 (1.06-4.86)
p for trend 0.67 p for trend 0.42
* adjusted for age, gender, BMI, school education, rehabilitation clinic,
smoking status, history of diabetes mellitus, PCI, CABG, left ventricular
function, HDL-cholesterol, LDL-cholesterol, treatment with lipid-lowering
drugs, NT-proBNP.
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recently described in a study including patients with
elective PCI and one year follow-up [19].
Limitations
We did not include other genetic polymorphisms that
are related to metabolic changes in platelet activation.
However, the carriage of *2 allele has been described in
95% of poor metabolizers [3]. Furthermore, this study
population consisted mostly of Caucasian, male patients
(85.0%), aged 50 – 70 years at baseline. Therefore,
results may have limited generalizability to females,
younger adults, or especially other ethnic groups as we
know that there is large variability for SNPs between
ethnic groups. However, the internal validity of our fin-
dings should not be affected. In addition, we considered
clopidogrel use at baseline and one year follow-up, but
the low prevalence probably reflects clinical practice a
decade ago.
Conclusions
Despite these limitations we conclude that in patients
with stable CHD homozygous carriers of the loss-of-
function allele CYP2C19*2 may be at increased risk for
subsequent CVD events, which may be especially high
in patients on clopidogrel. Whether early identification
of the few affected patients may allow a treatment stra-
tegy with improved outcomes should be investigated fur-
ther. However, the fact that few patients carrying the
homozygous loss-of-function variant has to be consi-
dered if assessing the clinical utility and benefit of geno-
typing in this patient population.
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